Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Capmatinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 05 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.